CME Presentations

Alzheimer's Management

Presentations

Speakers

  • Richard Isaacson, MD

    Richard Isaacson, MD

    Richard Isaacson, MD

    Director, Alzheimer's Prevention Clinic

    Richard Isaacson, MD, serves as Director of the Center for Brain Health and Director of the Alzheimer’s Prevention Clinic (APC) at Florida Atlantic University’s Schmidt College of Medicine. In addition, he is the Adjunct Associate Professor of Neurology in the Department of Neurology at Weill Cornell. Dr. Isaacson specializes exclusively in Alzheimer's disease (AD) risk reduction and treatment, mild cognitive impairment due to AD and pre-clinical AD. His AD research focuses on nutrition and the implementation and longitudinal assessment of dietary interventions for AD management. Dr. Isaacson’s recent efforts have focused on the development of Alzheimer's Universe a vast online educational portal on AD, with results published in the Journal of the Prevention of Alzheimer's disease.

    Session Appearances

    Advancing Alzheimer’s Disease Management: Strategies and Rationales for Early Diagnosis

  • Marwan Sabbagh, MD, FAAN

    Marwan Sabbagh, MD, FAAN

    Marwan Sabbagh, MD, FAAN

    Professor of Neurology

    Marwan Sabbagh, MD, FAAN, is a board-certified neurologist and geriatric neurologist, who has dedicated his career to finding a cure for Alzheimer’s and other age-related neurodegenerative diseases. Dr. Sabbagh is a leading investigator for many prominent national Alzheimer’s treatment trials. He has been recognized with numerous awards and is a Fellow of the American Academy of Neurology since 2004. Dr. Sabbagh is editor in chief of Neurology and Therapy, and he has authored and co-authored over 400 medical and scientific articles on Alzheimer’s research. Dr. Sabbagh is the author of The Alzheimer’s Answer: Reduce Your Risk and Keep Your Brain Healthy, with foreword by Justice Sandra Day O’Connor, and of The Alzheimer’s Prevention Cookbook: 100 Recipes to Boost Brain Health.

    Session Appearances

    Advancing Alzheimer’s Disease Management: Strategies and Rationales for Early Diagnosis

CME Information

Einstein Logo Montefiore Logo PQH Logo

Advancing Alzheimer’s Disease Management: Strategies and Rationales for Early Diagnosis

Presented by the Albert Einstein College of Medicine-Montefiore Medical Center
in Joint Providership with PlatformQ Health Education, LLC.

ACKNOWLEDGEMENT

This activity is supported by an educational grant from Eisai Inc.

TUITION

Complimentary

ACCREDITATION STATEMENT

In support of improving patient care, this activity has been planned and implemented by Albert Einstein College of Medicine-Montefiore Medical Center and PlatformQ Health. Albert Einstein College of Medicine-Montefiore Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

CREDIT DESIGNATION STATEMENTS

Live Internet Activity
Albert Einstein College of Medicine designates this internet live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Enduring Material
Albert Einstein College of Medicine designates this internet enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

OTHER CREDITS

The American Academy of Nurse Practitioners (AANP) and American Nurses Credentialing Center (ANCC) accept AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.

DATE OF RELEASE/EXPIRATION

Live Internet Activity: Tuesday, July 26, 2022 from 5:00 PM ET – 6:00 PM ET.

Enduring Material
The enduring material will be available from July 26, 2022 to July 26, 2023.

LEARNING OBJECTIVES

At the conclusion of this activity, participants will be able to:
  • Describe the current understanding of the pathophysiologic sequence of events that ultimately leads to AD, including the complex interplay between abnormal beta-amyloid and tau proteins leading to amyloid aggregation, neurofibrillary tangles, inflammation, and neuronal death
  • Review current and emerging assessment tools, biomarkers, and imaging techniques that can improve early diagnosis of AD and MCI
  • Summarize current clinical evidence supporting the efficacy and safety of new and investigational agents for MCI and early AD

INTENDED AUDIENCE

This activity is intended for US-based neurologists, geriatricians, dementia-trained providers (such as specialty nurse practitioners and physician assistants), and other clinicians who care for patients with AD.

ESTIMATED TIME TO COMPLETE

This activity should take approximately 1 hour to complete.

METHOD OF PARTICIPATION

There are no fees to participate in this activity. To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the posttest and activity evaluation. It is estimated that this module will take approximately 1 hour to complete. To receive AMA PRA Category 1 Credit™ participants must receive a minimum score of 70% on the posttest.

HARDWARE/SOFTWARE REQUIREMENTS

Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

FACULTY DISCLOSURE

The “Policy on Identification, Mitigation and Disclosure of Relevant Financial Relationships” of Albert Einstein College of Medicine-Montefiore Medical Center requires that faculty participating in any CME/CE activity disclose to the audience any relevant relationships with an ineligible company or companies.* Any presenter whose disclosed relationships prove to create a conflict of interest, with regard to his or her contribution to the activity, will not be permitted to present.

Albert Einstein College of Medicine-Montefiore Medical Center also requires that faculty participating in any CME/CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device, not yet approved in the United States. All financial relationships listed for individuals have been mitigated.

*The ACCME defines an ineligible company as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Presenter Disclosures
Richard Isaacson, MD
Director, Alzheimer's Prevention Clinic
Florida Atlantic University 		Consultant/Advisory Board: Acadia, Biogen, Genentech/Roche, Lilly (financial relationship with Biogen has ended)
Grant/Research Support: Mangurian Foundation
Unlabeled/unapproved drugs will be referenced: Lecanemab (BAN2401), Donanemab, Gantenerumab
Marwan Noel Sabbagh, MD, FAAN
Professor of Neurology
Barrow Neurological Institute
 Ownership interest (Stock or stock options): Athira, Cognoptix, Cortexyme, NeuroReserve, NeuroTau, Optimal Cognitive Health Company, Seq BioMarque, TransDermix, uMethod Health, Versanum,
Consultant: Alzheon, Biogen, Eisai, KeifeRx, Lilly, NeuroTherapia, Novo Nordisk, Roche-Genentech, Signant Health, Synaptogenix, T3D
Royalties: HarperCollins, Humanix
Unlabeled/unapproved drugs will be referenced:Lecanemab (BAN2401), Donanemab, Gantenerumab
Peer Reviewer Disclosures
David M. Kaufman, MD*
Professor of Neurology and Psychiatry
Albert Einstein College of Medicine
Montefiore Medical Center
Bronx, NY		 Has no relevant financial relationship with an ACCME-defined ineligible company in the last 24 months
PlatformQ Health Education, LLC Disclosures
Carole Drexel, Medical Director* Has no relevant financial relationship with an ACCME-defined ineligible company in the last 24 months
Colleen Heffner, Medical Director* Has no relevant financial relationship with an ACCME-defined ineligible company in the last 24 months
Jaimee Harris-Gold, Program Manager* Has no relevant financial relationship with an ACCME-defined ineligible company in the last 24 months

*Planner

CONTACT INFORMATION

Please send all inquiries to: Montefiore Medical Center, CCME, 3301 Bainbridge Avenue, Bronx, New York 10467, or via phone at (718) 920-6674, or via fax to (718) 798-2336, or via email to cme@montefiore.org.

For issues with your CME Certificate, please contact NeuroSeriesLive at 877-394-1306 or at Support@NeuroSeriesLive.com.

DISCLAIMERS (if applicable):

The material is prepared based on a review of multiple sources of information but is not exhaustive of the subject matter. Therefore, health care professionals and other individuals should review and consider other publications and materials about the subject matter other than relying solely on the information contained in this material.

The information presented at this CME program represents the views and opinions of the individual presenters, and does not constitute the opinion or endorsement of, or promotion by Albert Einstein College of Medicine-Montefiore Medical Center, NeuroSeriesLive, PlatformQ Health Education, LLC or the program grantor. Reasonable efforts have been made to present educational subject matter in a balanced, unbiased fashion and in compliance with regulatory requirements. Each participant must use his/her personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.